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ized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs).
Methods: Safety and efficacy data were analyzed for Indian (nZ 86) and Taiwanese (nZ 41)
patients hospitalized with cSSSIs who participated in two international Phase 3, randomized,
double-blind studies.
Results: Patients were treated for 5e14 days. Cure rates at the test-of-cure assessment (12e92
days post-therapy) were generally similar between tigecycline and vancomycin-aztreonam in
the clinically evaluable populations (India, 83.3% vs. 75.8%; Taiwan, 78.6% vs. 90%) and in the clin-
icalmodified intent-to-treat populations (India, 78.6% vs.66.7%; Taiwan, 73.3% vs. 75.0%). Nausea
and vomiting occurred more frequently with tigecycline, but overall safety and tolerability were
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Skin and skin structures are frequent sites of bacterial
infection, which can range from superficial, easily treated
local eruptions to deep aggressive infections that can
become life threatening.1 Complicated skin and skin
structure infections (cSSSIs) are considered to be those that
involve deep soft tissues, require surgical intervention, or
occur in patients with comorbidities such as diabetes,
peripheral neuropathy, and peripheral vascular disease.2,3
cSSSIs often develop during hospitalization for surgery or
trauma, and place patients at risk for not only wound
infection but also pneumonia and sepsis. These infections
prolong hospital stays, increase morbidity and mortality,
and increase the cost of patient care.2
The agents most frequently implicated in cSSSIs include
gram-positive organisms such as Staphylococcus aureus and
Streptococcus pyogenes, as well as Enterobacteriaceae and
aerobic nonfermenters such as Pseudomonas aeruginosa
and Acinetobacter spp. Mixed infections that include gram-
negative bacilli and anaerobic bacteria are often encoun-
tered in complicated cases. Although there has been little
change in the incidence and distribution of pathogens iso-
lated from cSSSIs, international surveillance data document
an increase in resistance worldwide among both gram-
positive and gram-negative organisms to a variety of anti-
microbial classes.4,5 Methicillin-resistant S aureus (MRSA) in
particular is of increasing concern, as up to 21% of skin
infections are now caused by this agent.2 MRSA infection
has usually been associated with exposure to health care
settings, but community-associated MRSA with unique
virulence and clonal characteristics has now become
a widespread cause of skin and soft tissue infections.6,7
Tigecycline is an expanded broad-spectrum glycylcycline
antibiotic that was designed to overcome the two major
determinants of tetracycline resistance, drug efflux, and
ribosomal protection.8e10 As a single antimicrobial agent,
tigecycline offers broad antibiotic coverage against many
pathogens associated with cSSSIs, including MRSA and many
species of multidrug-resistant gram-negative bacteria,11,12
although it provides no coverage against P aeruginosa.
Two independent global Phase 3 trials, as well as
a pooled analysis of the trials, have demonstrated that
monotherapy with tigecycline is as effective as the
combination of vancomycin and aztreonam for treating
hospitalized patients with cSSSIs.13e15 The North American/
South American study was conducted in the Americas and
India, whereas the worldwide study was conducted in
Europe, Asia, Australia, and South Africa. In these Phase 3
studies, only patients from the Asia-Pacific countries of
India and Taiwan were enrolled, and this article focuses on
these two geographic subpopulations of patients sepa-
rately, to avoid potential confounding by racial factors,
while detailing the efficacy of tigecycline in treating cSSSIs
in patients from these countries.Methods
The study design and methods for the two original clinical
trials were similar and have been described in detail else-
where.13e15 A brief summary is presented here.
Study design
Two Phase 3 multicenter, randomized, double-blind studies
were conducted in hospitalized patients with cSSSIs. The
North American/South American study was conducted
between August 2001 and February 2004 at 89 sites in 8
countries, including 9 sites in India. The worldwide study
was conducted between November 2002 and December
2003 at 65 centers in 21 countries, including 3 sites in
Taiwan. The studies were approved by the Institutional
Review Board or Ethics Committee at participating institu-
tions and were conducted according to the recommenda-
tions of the Declaration of Helsinki. All patients gave
written informed consent to participate in the study.
Patients were randomly assigned (1:1) to receive either
tigecycline [initial intravenous (IV) dose of 100 mg in
250 mL saline followed by 50 mg IV every 12 hours] or IV
vancomycin-aztreonam (1 g vancomycin in 250 mL saline
followed by 2 g aztreonam in 100 mL saline, each every 12
hours). Patients treated with tigecycline also received
a 100-mL infusion of normal saline placebo after infusion of
tigecycline to maintain study blinding. The duration of
treatment was 5e14 days unless a patient was deemed
a clinical failure after receiving at least four doses of study
drug. The test-of-cure assessment was made 12e92 days
after the last dose was administered. Wound irrigation with
antiseptics and other standard treatment measures was
allowed, but other systemic or topical antibiotics or
steroids were not permitted.
Patients
The eligible population included hospitalized patients 18
years of age with cSSSIs that involved deep soft tissue,
required surgical intervention (including extensive cellulitis
of at least 10 cm in width or length), or were associated
with significant underlying disease (diabetes mellitus,
peripheral vasculopathy, peripheral neuropathy, or lower
venous insufficiency). Furthermore, patients had to exhibit
two of the following signs and symptoms of infection:
drainage or discharge, fever, erythema, swelling, localized
warmth, pain, or white blood cell count >10  109/L.
Patients were excluded if they had necrotizing fasciitis,
gangrene, osteomyelitis, required plasmapheresis, or
hemoperfusion, had neutropenia, severely impaired arte-
rial supply that would predict amputation within 1 month,
or any condition that could impair eradication of infection.
Patients with severe hepatic disease or hypersensitivity to
the study drugs were excluded.
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Patients who met eligibility criteria were randomly assigned
to treatment and comprised the intent-to-treat (ITT) pop-
ulation. The modified ITT (mITT) (safety) population con-
sisted of patients who received at least one dose of study
medication. Patients in themITT populationwho had clinical
evidence of cSSSI by meeting the minimal disease criteria
were included in the clinical mITT (c-mITT) population.
Patients in the c-mITT population were considered to be
clinically evaluable (CE) if they met inclusion and exclusion
criteria, did not have P aeruginosa as a sole baseline isolate,
received no concomitant antibiotic after the first dose of
study medication, received appropriate and sufficient
treatment to determine cure or failure, remained blinded,
and had an assessment of “cure” or “failure” at the test-of-
cure (TOC) visit 12e92 days after the last dose of study
medication. Themicrobiologically evaluable (ME) population
consisted of CE patients who had at least one identifiable
baseline isolate that was susceptible to both study medica-
tions and who had a microbiologic outcome (eradication,
persistence, superinfection) at the TOC visit.Assessments
The primary efficacy endpoint was the clinical response in the
coprimary CE and c-mITT populations at the TOC visit (12e92
days after therapy). An investigator blinded to treatment
assessed drainage or discharge, fever, erythema, swelling or
induration, pain or tenderness to palpation, extent of infec-
tion, and localized warmth. Based on these assessments, the
clinical outcome was designated as “cure”, “failure”, or
“indeterminate”.A patientwas considered cured if symptoms
resolved or improved so that no further antibacterial therapy
was required. An outcome was designated a failure if addi-
tional antibacterial therapy or an unplanned surgical inter-
vention for this infectionwas requiredor if a patient died from
infection >2 days after randomization, discontinued therapy
because of treatment-related adverse events, or received
>120% of the prescribed treatment doses. The outcome was
considered indeterminate if death occurred within 2 days of
randomization or was not related to infection before the TOC
visit, or if no evaluation was possible.
The clinical response (cure or failure) by baseline isolate
and type of infection (monomicrobial vs. polymicrobial) was
a secondary endpoint and was evaluated with data from the
ME population.
Microbiologic efficacy was evaluated at both the patient
level (eradication, persistence, superinfection, or indeter-
minate) and the pathogen level (eradication, persistence,
or indeterminate) for baseline isolates. Skin cultures were
the principal source of the baseline isolates. All recovered
isolates were subcultured and sent to a central laboratory
for confirmation. Furthermore, to evaluate the sensitivity
of isolates to tigecycline, vancomycin, and aztreonam,
minimum inhibitory concentrations (MICs) were determined
using procedures published by the Clinical and Laboratory
Standards Institute (formerly National Committee for Clin-
ical Laboratory Standards).16e18
The safety population comprised all patients who
received at least one dose of study drug, that is, the mITTpopulation. Safety assessments included a physical exami-
nation and 12-lead electrocardiogram at baseline. Vital
signs were recorded daily; hematologic, blood chemistry,
and coagulation parameter evaluations were performed at
baseline, at regularly scheduled visits during treatment,
and at the TOC visit. Adverse events were recorded
throughout the study period.
Statistical analyses
In the main Phase 3 studies, the noninferiority of tigecycline
compared with vancomycin-aztreonam was evaluated for
clinical and microbiologic responses with a two-sided 95%
confidence interval for the true difference in efficacy. Non-
inferiority was concluded if the lower limit of the two-sided
95% confidence interval was no lower than 15%. The effi-
cacy analysis plan was based on a sample size of at least 300
CE patients to allow a 90% probability of detecting a true
difference inefficacyof not less than15%between treatment
groups. However, the current analysis of patients from India
and Taiwan was a retrospective post hoc analysis and
because of insufficient numbers of patients enrolled in both
countries, no formal statistical inference could be used to
evaluate the efficacy of tigecycline. Hence, findings from
these two countries were reviewed mainly for consistency
with the results from the respective overall studies.
Results
Table 1 shows the distribution of patients in the various
analysis populations for both India and Taiwan. Of 596
subjects randomized to treatment in the main North
American/South American study, 86 were from India and all
received at least one dose of study drug (mITT population).
Of these, 63 patients met the clinical evaluability criteria
(CE population) and 37 of these patients were considered
ME. The worldwide study randomized 546 patients, of
which 42 were from Taiwan; 41 Taiwanese patients
received at least one dose of study drug (mITT population).
The CE and ME populations consisted of 24 and 8 patients,
respectively. The numbers of patients in the two treatment
groups were similar within each subpopulation.
Baseline clinical and demographic characteristics were
generally well-matched between the two treatment groups in
both Indian and Taiwanese patients (Table 2). Compared with
the overall worldwide study population, patients fromTaiwan
were older (median age, 52 years vs. 49 years) and had lower
body weights (median, 74.5 kg vs. 79.0 kg). Furthermore, in
comparison with their respective overall trial populations,
Taiwanese patients had a higher incidence of deep soft tissue
infection (95.1% for Taiwanese patients vs. 58e61% in the
larger trial population), and patients from India had a higher
frequency of diabetes mellitus (41.9% for patients from India
vs. 29e31% in the overall trial population).
Clinical and microbiologic responses
Indian patients
In the Indian subpopulation, clinical responses in the
coprimary CE and c-mITT populations were higher in the
tigecycline group than in the vancomycin-aztreonam group
Table 1 Patient disposition
Population India Taiwan
Tigecycline Vancomycin-
aztreonam
Total Tigecycline Vancomycin-
aztreonam
Total
n (%ITT) n (%ITT) n (%ITT) n (%ITT) n (%ITT) n (%ITT)
Screened 95 42
Screen failures 9 0
Intent-to-treat (ITT) 44 42 86 20 22 42
Modified ITT (mITT) 44 (100) 42 (100) 86 (100) 19 (95.0) 22 (100) 41 (97.6)
Clinical mITT (c-mITT) 42 (95.5) 42 (100) 84 (97.7) 15 (75.0) 16 (72.7) 31 (73.8)
Clinically evaluable (CE) 30 (68.2) 33 (78.6) 63 (73.3) 14 (70.0) 10 (45.5) 24 (57.1)
Microbiologically
evaluable (ME)
17 (38.6) 20 (47.6) 37 (43.0) 3 (15.0) 5 (22.7) 8 (19.0)
cSSSI Z complicated skin and/or skin structure infection; c-mITT Z mITT subjects with evidence of cSSSI. ITT Z all randomized
subjects; mITT Z ITT subjects who received at least one dose of study drug.
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were 83.3% (25/30 patients) with tigecycline, compared
with 75.8% (25/33 patients) with vancomycin-aztreonam; in
the c-mITT population, cure rates with tigecycline were
78.6% (33/42 patients) versus 66.7% (28/42 patients) withTable 2 Baseline demographic and clinical characteristics (mIT
Characteristics India
Tigecycline
(n Z 44)
Vanco
(n Z 4
Age (yr) 50.8  14.9 51.1 
Male sex 31 (70.5) 32 (76
Female sex 13 (29.5) 10 (23
Weight (kg) 63.4  11.3 62.5 
Creatinine clearance (mL/min) 81.6  31.2 78.4 
Primary clinical diagnosis
Deep soft tissue infection 20 (45.5) 24 (57
Cellulitis 19 (43.2) 20 (47
Complicated underlying disease 4 (9.1) 9 (21.4
10 cm (where
anatomically applicable)
19 (43.2) 18 (42
Requiring surgery/drainage 7 (15.9) 10 (23
Wound infection 1 (2.3) 4 (9.5)
Major abscesses 17 (38.6) 13 (31
Infected ulcers 6 (13.6) 4 (9.5)
Other 1 (2.3) 1 (2.4)
Comorbid conditions
Diabetes mellitus 18 (40.9) 18 (42
Peripheral vascular disease 0 0
Cause of infection
Trauma 8 (18.2) 13 (31
Spontaneous 32 (72.7) 23 (54
Bite (human, insect, animal) 1 (2.3) 1 (2.4)
Surgery 0 4 (9.5)
Other 3 (6.8) 1 (2.4)
Data are presented as mean  standard deviation or n(%).
mITT Z modified intent-to-treat; SD Z standard deviation.vancomycin-aztreonam. The noninferiority of tigecycline
among Indian patients could not be evaluated statistically
because of insufficient sample size.
Tables 4 and 5 present clinical and microbiologic
responses in the ME population at the TOC visit for selectedT population)
Taiwan
mycin-aztreonam
2)
Tigecycline
(n Z 19)
Vancomycin-aztreonam
(n Z 22)
17.1 53.0  19.9 55.3  20.3
.2) 14 (73.7) 11 (50.0)
.8) 5 (26.3) 11 (50.0)
15.5 75.7  16.2 71.7  13.3
36.7 93.7  31.6 81.8  30.4
.1) 19 (100.0) 20 (90.9)
.6) 19 (100.0) 20 (90.9)
) 4 (21.1) 8 (36.4)
.9) 18 (94.7) 17 (77.3)
.8) 5 (26.3) 6 (27.3)
0 0
.0) 0 1 (4.5)
0 1 (4.5)
0 0
.9) 3 (15.8) 6 (27.3)
1 (5.3) 4 (18.2)
.0) 4 (21.1) 6 (27.3)
.8) 13 (68.4) 16 (72.7)
1 (5.3) 0
1 (5.3) 0
0 0
Table 3 Cure rate at the test-of-cure visit in patients from India and Taiwan (CE and c-mITT populations)
India Taiwan
Tigecycline Vancomycin-aztreonam Tigecycline Vancomycin-aztreonam
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
CE population 25/30 83.3 (65.3e94.4) 25/33 75.8 (57.7e88.9) 11/14 78.6 (49.2e95.3) 9/10 90.0 (55.5e99.7)
c-mITT population 33/42 78.6 (63.2e89.7) 28/42 66.7 (50.5e80.4) 11/15 73.3 (44.9e92.2) 12/16 75.0 (47.6e92.7)
CE Z clinically evaluable; CI Z confidence interval; c-mITT Z clinical modified intent-to-treat.
120 Y.-C. Chuang et al.isolates of clinical interest. The number of isolates was
small and no definitive inferences are possible. However,
tigecycline demonstrated antimicrobial efficacy against
isolates commonly linked to cSSSIs, including Enterococcus
faecalis, Escherichia coli, S aureus, and Streptococcus
agalactiae, both as monomicrobial and polymicrobial
infections. There were no MRSA isolates among the Indian
patients. Of six patients from whom S aureus (non-MRSA)
was isolated as part of a polymicrobial infection, the one
patient treated with tigecycline was cured, compared with
two cured out of the five placed on vancomycin-aztreonam
(Table 5). For methicillin-susceptible S aureus, the tigecy-
cline MIC90 value was 0.25 mg/mL (range, 0.12e0.25 mg/mL)
compared with a MIC90 value of 1.0 mg/mL for vancomycin
(range, 1.0e2.0 mg/mL). MIC ranges for E coli
(0.12e0.50 mg/mL) and E faecalis (0.06e0.25 mg/mL)
isolates were also lower for tigecycline than for vancomycin
(128.0 mg/mL and 2.0 mg/mL, respectively) or aztreonam
(0.12 mg/mL and 128.0 mg/mL, respectively).
Taiwanese patients
Among Taiwanese patients, cure rates in the CE population
were lower with tigecycline (78.6%, 11/14 patients) than
with vancomycin-aztreonam (90.0%, 9/10 patients),
whereas there was no difference in cure rates between the
two treatments in the c-mITT population [tigecycline,
73.3% (11/15 patients); vancomycin-aztreonam, 75.0%Table 4 Clinical and microbiologic responses by selected base
India and Taiwan
Isolate Tigecycline 50 mg Va
Clinical cure
(n/N)
Microbiological
eradication (n/N)
Cli
cu
India
Enterococcus faecalis
(non-VRE)
1/1 1/1 2/
Staphylococcus aureus
(MSSA)
1/1 1/1 2/
Escherichia coli 1/2 1/2 0/
Streptococcus agalactiae 1/1 1/1 0/
Taiwan
S aureus (MRSA) 1/1 1/1 0/
S aureus (MSSA) 0/0 0/0 2/
E faecalis 0/0 0/0 1/
a Includes subjects who received vancomycin.
b Includes subjects who received aztreonam.
MRSA Z methicillin-resistant S aureus; MSSA Z methicillin-susceptib(12/16 patients)]. The sample size was too small to be able
to draw any conclusions.
Clinical responses and microbiologic eradication rates for
selected isolates in the Taiwanese ME population are shown
in Tables 4 and 5. There were few isolates available for
analysis. One patient had an MRSA infection, which respon-
ded to tigecycline. The MIC of tigecycline against this MRSA
isolatewas low (0.25mg/mL), aswere theMICs tomethicillin-
susceptible S aureus (0.12 mg/mL) and E faecalis (0.12 mg/
mL); these isolates displayed higher MICs to vancomycin, of
2.0 mg/mL, 1.0 mg/mL, and 1.0 mg/mL, respectively.
Safety
Data from patients in the mITT populations (86 patients in
India and 41 in Taiwan) were analyzed for safety and
tolerability (Table 6). Patients in India received treatment
with tigecycline or vancomycin-aztreonam over a median of
7.0 days (range, 1e15 days), whereas the median duration
of treatment was 11 days (range, 1e14 days) for patients in
Taiwan.
Indian patients
In India, the overall frequency of adverse events was signif-
icantly higher among tigecycline-treated patients (90.9%)
than among vancomycin-aztreonam-treated patients (73.8%)
(pZ 0.048). Tigecycline was associated with a significantlyline isolate in the microbiologically evaluable population in
ncomycina Aztreonamb
nical
re (n/N)
Microbiological
eradication (n/N)
Clinical
cure (n/N)
Microbiological
eradication (n/N)
3 2/3 2/3 2/3
5 3/5 2/5 3/5
0 0/0 0/0 0/0
0 0/0 0/0 0/0
0 0/0 0/0 0/0
2 2/2 2/2 2/2
1 1/1 1/1 1/1
le S aureus; VRE Z vancomycin-resistant Enterococcus.
Table 5 Clinical and microbiologic responses by selected baseline isolate and MIC values in microbiologically evaluable
subjects in India and Taiwan
Isolate MIC
(mg/mL)
Tigecycline Vancomycina Aztreonamb
Clinical
cure (n/N )
Microbiological
eradication (n/N )
Clinical
cure (n/N )
Microbiological
eradication (n/N )
Clinical
cure (n/N )
Microbiological
eradication (n/N )
India
Enterococcus
faecalis (non-VRE)
0.25 1/1 1/1 0/0 0/0 0/0 0/0
2 0/0 0/0 2/3 2/3 0/0 0/0
128 0/0 0/0 0/0 0/0 2/3 2/3
Total 1/1 1/1 2/3 2/3 2/3 2/3
Escherichia coli 0.12 1/1 1/1 0/0 0/0 0/0 0/0
0.5 0/1 0/1 0/0 0/0 0/0 0/0
Total 1/2 1/2 0/0 0/0 0/0 0/0
Staphylococcus
aureus (MSSA)
0.12 1/1 1/1 0/0 0/0 0/0 0/0
1 0/0 0/0 2/5 3/5 0/0 0/0
128 0/0 0/0 0/0 0/0 2/5 3/5
Total 1/1 1/1 2/5 3/5 2/5 3/5
Streptococcus
agalactiae
0.06 1/1 1/1 0/0 0/0 0/0 0/0
Total 1/1 1/1 0/0 0/0 0/0 0/0
Taiwan
Non-fermentative
gram-negative rod
0.5 0/0 0/0 1/1 1/1 0/0 0/0
1 0/0 0/0 0/0 0/0 1/1 1/1
Total 0/0 0/0 1/1 1/1 1/1 1/1
E faecalis 1 0/0 0/0 1/1 1/1 0/0 0/0
128 0/0 0/0 0/0 0/0 1/1 1/1
Total 0/0 0/0 1/1 1/1 1/1 1/1
S aureus (MSSA) 1 0/0 0/0 2/2 2/2 0/0 0/0
128 0/0 0/0 0/0 0/0 2/2 2/2
Total 0/0 0/0 2/2 2/2 2/2 2/2
S aureus (MRSA) 0.25 1/1 1/1 0/0 0/0 0/0 0/0
Total 1/1 1/1 0/0 0/0 0/0 0/0
Streptococcus
dysgalactiae
0.5 0/0 0/0 1/1 1/1 0/0 0/0
64 0/0 0/0 0/0 0/0 1/1 1/1
Total 0/0 0/0 1/1 1/1 1/1 1/1
a Includes subjects who received vancomycin.
b Includes subjects who received aztreonam.
MEZmicrobiologically evaluable; MICZminimum inhibitory concentration; MRSAZmethicillin-resistant S aureus; MSSAZmethicillin-
susceptible S aureus; VRE Z vancomycin-resistant Enterococcus.
Tigecycline monotherapy in cSSSIs 121higher frequency of adverse gastrointestinal events (47.7%
vs. 16.7%; p Z 0.003), the most commonly reported
gastrointestinal events being vomiting (31.8% vs. 9.5%,
pZ 0.016), diarrhea (13.6% vs. 0%, pZ 0.026), and nausea
(22.7% vs. 7.1%, pZ 0.069). The incidence of nausea and/or
vomiting was 40.9% with tigecycline treatment, compared
with 11.9% with vancomycin-aztreonam (p Z 0.003), and
the use of antiemetic or antinausea medication was signifi-
cantly higher in the tigecycline group (25% vs. 7.1%,
p Z 0.039). The majority of cases of nausea or vomiting
(approximately 90%) were mild or moderate (Grade 1 or 2).
One patient in the vancomycin-aztreonam groupdiscontinued treatment because of nausea, and one patient
in the tigecycline group withdrew consent because of vom-
iting, which he felt was because of test article. Other
adverse events that occurred significantly more frequently
with tigecycline treatment included coagulation system
abnormalities, including prolonged prothrombin time
(27.3% vs. 7.1%, pZ 0.02) and prolonged activated partial
thromboplastin time (38.6% vs. 14.3%, pZ 0.015). Elevated
serum amylase levels were also more frequently associated
with tigecycline treatment.
Four deaths occurred among Indian patients, three in
the tigecycline group (one was the result of septic shock
Table 6 Safety of tigecycline versus vancomycin þ aztreonam in patients from India and Taiwan (mITT population)
India Taiwan
Tigecycline
(n Z 44)
Vancomycin-aztreonam
(n Z 42)
Tigecycline
(n Z 19)
Vancomycin-aztreonam
(n Z 22)
Any adverse event 40 (90.9)* 31 (73.8) 18 (94.7) 19 (86.4)
Adverse events differing
significantly between groups
Digestive system 21 (47.7)** 7 (16.7) 14 (73.7)** 6 (27.3)
Anorexia 0 0 7 (36.8)** 0
Diarrhea 6 (13.6)* 0 2 (10.5) 0
Nausea 10 (22.7) 3 (7.1) 8 (42.1)** 1 (4.5)
Vomiting 14 (31.8)* 4 (9.5) 7 (36.8)* 1 (4.5)
Hemic and lymphatic system 25 (56.8)** 11 (26.2) 1 (5.3) 0
Prolonged APTT 17 (38.6)* 6 (14.3) 1 (5.3) 0
Prolonged prothrombin time 12 (27.3)* 3 (7.1) 1 (5.3) 0
Increased serum amylase level 6 (13.6) 0 e e
Headache 2 (4.5) 0 4 (21.1)* 0
Death 3 1 0 0
Serious adverse events 9 (20.5) 10 (23.8) 2 (10.5) 2 (9.1)
Treatment discontinuation for adverse event 3 (6.8) 6 (14.3) 1 (5.3) 1 (4.5)
Withdrawal from study for adverse event 5 (11.4) 7 (16.7) 0 2 (9.1)
* Significant between group difference at <0.05 level.
** Significant between group difference at <0.01 level.
APTT Z Activated partial thromboplastin time; mITT Z modified intent-to-treat.
122 Y.-C. Chuang et al.that was present before the study and the other two were
caused by a perforated duodenal ulcer and myocardial
infarction, respectively), and one in the comparator group
(caused by chronic obstructive pulmonary disease). All
deaths were considered probably not or definitely not
related to the study drugs. Serious adverse event rates
were comparable between the two treatment groups, with
an overall frequency of 22.1% (19/86 patients).
Adverse events were the main reasons for discontinuation
of the study drugs (tigecycline, three patients; vancomycin-
aztreonam, 6 patients). No single event predominated with
respect to early treatment discontinuation in the tigecycline
group, but in the vancomycin-aztreonam group, four patients
discontinued treatment because of rash or pruritus. Twelve
patients withdrew from the study because of adverse events:
five in the tigecycline group and seven in the vancomycin-
aztreonam group. The primary events leading to withdrawal
were nausea and vomiting in three patients with tigecycline
and rashorpruritus in fourpatientswho receivedvancomycin-
aztreonam.Nosignificantchanges in laboratoryparametersor
in vital signs occurred in either treatment group.
Taiwanese patients
In patients from Taiwan, overall adverse event rates were
comparable between the tigecycline and vancomycin-
aztreonam groups, but patients receiving tigecycline expe-
rienced a significantly higher frequency of headache (21.1%
vs. 0%, pZ 0.038) and adverse gastrointestinal events (73.7%
vs. 27.3%, p Z 0.005). Nausea and/or vomiting occurred in
10/19 patients (52.6%) in the tigecycline group, compared
with 2/22 (9.1%) in the vancomycin-aztreonam group
(pZ 0.005), but all cases except oneweremild tomoderate.
Only one patient discontinued treatment because of nauseaand vomiting. Anorexia was reported by seven patients who
received tigecycline (36.8%) and by none of the patients
receiving vancomycin-aztreonam (pZ 0.002). More patients
treated with vancomycin-aztreonam had rash or pruritus (9/
22, 40.9% vs. 5/19, 26.3%), but this was not a statistically
significant difference.
No deaths occurred in Taiwanese patients, and two
patients in each group experienced a serious adverse event.
One patient in each group discontinued therapy because of
an adverse event (nausea and vomiting in a patient trea-
ted with tigecycline and pruritus and rash in a patient in
the vancomycin-aztreonam group). There were no study
withdrawals because of adverse events among tigecycline-
treated patients, but two patients in the vancomycin-
aztreonam group withdrew because of multiple adverse
experiences including pruritus and rash.
Discussion
This subanalysis of the pivotal tigecycline studies shows
that monotherapy with tigecycline is a safe and effective
treatment of cSSSIs in the subpopulation of hospitalized
patients from India and Taiwan. The efficacy of tigecycline
in these patients was generally similar to that of the
combination of vancomycin and aztreonam. Both treat-
ments were well tolerated and the adverse event profiles of
both treatments were similar to those previously reported.
The efficacy results for tigecycline in Indian and Taiwa-
nese patients with cSSSIs are generally consistent with
those reported in the overall Phase 3 studies as well as in
the pooled efficacy analysis of the Phase 3 studies. In both
CE and c-mITT populations in India, clinical cure rates were
numerically higher with tigecycline than with vancomycin-
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83.3% with tigecycline and 75.8% with vancomycin-aztreo-
nam. These rates are similar to those reported in the North
American/South American study overall, namely, 82.9%
with tigecycline and 82.3% with vancomycin-aztreonam.13
Similarly, in the c-mITT population, the cure rate of 78.6%
with tigecycline in India is similar to the rate of 75.5% in the
overall study subjects, whereas the cure rate with vanco-
mycin-aztreonam was somewhat lower among Indian
patients (66.7% vs. 76.9% in the overall study).
The data from Taiwan are based on smaller patient
numbers, with only 24 and 31 patients comprising the total
CE and c-mITT populations, respectively. Although clinical
responses to tigecycline in both the CE (78.6%) and the c-
mITT population (73.3%) were lower than those obtained
with the larger population in the worldwide trial (89.7% in
the CE population and 84.3% in the c-mITT population),14
the results are generally consistent with those from the
pooled analysis of the pivotal Phase 3 studies (86.5% and
79.7% in the CE and c-mITT patients, respectively).15 The
numbers of patients enrolled in both India and Taiwan were
insufficient for any statistical inference about the efficacy
of tigecycline compared with that of the comparator. In
both the North American/South American study and the
worldwide study, the efficacy of tigecycline monotherapy
was statistically similar to that of vancomycin-aztreonam.
The current analysis suggests that, as in the larger studies,
the efficacy of tigecycline is comparable to that of vanco-
mycin-aztreonam in patients from India and Taiwan.
No new safety concerns emerged in Indian or Taiwanese
patients after treatment with tigecycline, and the findings
in general support the safety data from the full Phase 3
studies.13e15 The main adverse events experienced with
tigecycline were nausea and vomiting, which occurred
significantly more frequently than with vancomycin-
aztreonam. However, these events were mild to moderate,
were controlled with appropriate therapy, and rarely
resulted in discontinuation of study drug. Other adverse
events associated more frequently with tigecycline treat-
ment were an increased incidence of headache among
Taiwanese patients and prolongation of prothrombin and
activated partial thromboplastin times among Indian
patients. These laboratory observations do not appear to be
clinically significant as treatment with tigecycline was not
associated with an enhanced risk of bleeding or bruising.
All patients receiving vancomycin-aztreonam, and 97%
of patients receiving tigecycline were also receiving other
medications, including anticoagulants (9.1% of patients
treated with tigecycline and 7.1% of patients treated with
vancomycin-aztreonam). None of the patients in this report
were receiving warfarin.
Adverse events involving the skin, such as pruritus, were
observed more frequently with vancomycin-aztreonam. Both
treatments were comparable with respect to the incidence of
death, serious adverse events, and treatment discontinuation.
IV antibiotics are often used to treat cSSSIs.19 Vancomycin
has historically been considered the agent of choice for
treating MRSA, but its efficacy is being challenged by strains
with reduced susceptibility, which have been reported
worldwide.20,21 These shifts in susceptibility reduce theability
of clinicians to treat patients appropriately with empiric
therapy. For patientswith serious infections, the initial choicefor empiric therapywithbroad-spectrumantibiotics is crucial,
as an inappropriate antibiotic may contribute to treatment
failure,with serious adverse consequences.2,22 The increasing
loss of broad-spectrum coverage because of emergence of
resistance to established therapies for many pathogens has
created a critical need for new antimicrobial agents.
In Phase 3 studies, tigecycline demonstrated microbiologic
efficacy against many bacterial isolates linked to cSSSIs, and
notably, 78% of cSSSIs attributable to MRSA were eradicated
with tigecycline (compared with 76% with vancomycin-aztreo-
nam).15 The excellent broad-spectrum activity of tigecycline
against clinical isolates from patients in these cSSSI studies,
excluding those patients with P aeruginosa as a primary base-
line isolate, was confirmed by a susceptibility study in vitro, in
which tigecycline displayed consistently low MIC90 values for
the most prevalent pathogens associated with cSSSI.12 This
study, which tested worldwide isolates, found no regional
differences in the susceptibility to tigecycline of isolates. Of
interest with respect to the current analysis was the demon-
stration that the MIC90 of tigecycline against methicillin-sensi-
tiveSaureusandEcoli isolates from Indiawas similar to that for
isolates of these pathogens from other countries.
cSSSIs in the hospital are almost always treated with anti-
microbial agents, and at least initially, therapy is empiric.
However, empiric management decisions are complicated by
the diverse bacterial etiology of these infections and the
constantly evolving patterns of resistance among the causa-
tive pathogens.23 Because of its expanded spectrum of
activity, tigecycline is a promising agent for treating cSSSIs in
hospitalized patients, particularly when broad empiric
coverage is needed. Unlike vancomycin, which requires
additional coverage for gram-negative organisms, tigecycline
can be administered as a single agent. Thus, compared with
vancomycin-aztreonam, tigecycline monotherapy offers
similar efficacy and tolerability withmore convenient dosing.
This retrospective analysis demonstrates that monotherapy
with tigecycline is generally safe, effective, and comparable
to vancomycin-aztreonam for treating hospitalized patients
with cSSSIs in India and Taiwan.
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